Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
企業コードSMTI
会社名Sanara Medtech Inc
上場日Apr 07, 1994
最高経営責任者「CEO」Muppalla (Suresh V)
従業員数141
証券種類Ordinary Share
決算期末Apr 07
本社所在地1200 Summit Avenue
都市FORT WORTH
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号76102
電話番号18175292300
ウェブサイトhttps://sanaramedtech.com/
企業コードSMTI
上場日Apr 07, 1994
最高経営責任者「CEO」Muppalla (Suresh V)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし